|
The previously-recorded webcasts and the information
contained in the presentations included in this section
are provided as a service to investors and other
interested parties. While such information was accurate,
in all material respects, at the time of its original
presentation, the Company has undertaken no obligation
whatsoever to update, correct or otherwise modify any of
the information contained in these presentations.
Accordingly, YOU SHOULD NOT RELY ON THE ACCURACY OF ANY
OF THE STATEMENTS IN THE PRESENTATION OR ANY OTHER
INFORMATION CONTAINED IN THIS SECTION. Furthermore,
these presentations may contain "forward-looking
statements" as defined in the Private Securities
Litigation Reform Act of 1995. These statements, at the
time they were made, were based on then-current
expectations of future events. If any of those
underlying assumptions prove or have proven to be
inaccurate or unknown or if risks or uncertainties
materialize or have materialized, actual results could
vary or already may have varied materially from the
Company's expectations and projections in these
presentations. These risks and uncertainties include
general industry conditions and competition; economic
conditions, such as interest rate and currency exchange
rate fluctuations; technological advances and patents
attained by competitors; challenges inherent in new
product development, including obtaining regulatory
approvals; domestic and foreign health care reforms and
governmental laws and regulations; and trends toward
health care cost containment. Actual results could vary
materially from those described as a result of a number
of factors, including those set forth in Discovery’s
Annual Report on Form 10-KSB and any subsequent SEC
filings, as they may have been amended.
The Company assumes no obligation to update any
forward-looking statements or any other information
contained herein as a result of new information or
future events or developments.
This presentation does not constitute an offer to purchase
any securities, nor a solicitation of a proxy, consent
or agent designation with respect to a meeting of the
Company’s stockholders. |
